

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in this application.

Listing of Claims

Claim 1 (currently amended) ~~Use of γ -GT inhibitors for the preparation of a pharmaceutical composition for the treatment of~~ A method of treating a degenerative disease in a subject in need thereof, comprising the step of inhibiting γ -GT activity in said subject.

Claim 2 (currently amended) The ~~use~~ method of claim 1, wherein said degenerative disease is a chronic renal disease or an inner ear degenerative condition or injury.

Claim 3 (currently amended) The ~~use~~ method of claim 2 wherein said chronic renal disease is ROS induced.

Claim 4 (currently amended) The ~~use~~ method of claim 3, wherein said chronic renal disease is selected from the group consisting of focal glomerulosclerosis, segmental glomerulosclerosis,

minimal change nephrosis, inflammatory glomerulopathies, diabetic nephropathy and autoimmune glomerulopathies.

Claim 5 (currently amended) The ~~use~~method of claim 2, wherein said inner ear injury is ROS induced.

Claim 6 (currently amended) The ~~use~~method of claim 5, wherein said ROS induced inner ear injury is sensineural deafness induced by age, physiological status, metabolic status or drugs.

Claim 7 (currently amended) The ~~use~~method of claim 6, wherein said drugs are selected from aminoglycosides or cisplatin derivatives.

Claim 8 (currently amended) The ~~use~~method of claim 2, wherein said inner ear degenerative condition is otosclerosis.

Claim 9 (currently amended) The ~~use~~method of any one of claims 1 to 8, wherein said γ -GT inhibitor is selected from the group consisting of AT-125[[,]] (Acivicin) or its derivatives, γ -glutamyl amino acids and peptides of the general formula γ -Glu-XY, peptides of the general formula (CysGlyX), peptidomimetic glutathion analogues, compounds or derivatives of the

Application No. 10/644,325
Response dated December 8, 2004
Response to Restriction Requirement dated October 8, 2004

type L-2-amino-4-boronobutanoic acid (ABBA), and anilides, such as γ -glutamyl-7-amido-4-methylcoumarin (γ -Glu-AMC).

Claim 10 (currently amended) The ~~use~~ method of claim 9, wherein X and Y stand for any naturally occurring aminoacid, a modified aminoacid, a oligopeptide or a polypeptide.